PRVB News and Press, Provention Bio Inc. From 08/04/22

Provention Bio Reports Second Quarter 2022 Financial Results and Provides Business Update PR Newswire -Teplizumab Biologics License Application (BLA) user fee goal date extended to November 17, 2022 - -Company completes $60.0 million private placement- ...

Provention Bio ( NASDAQ: PRVB ) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is -$0.50 (-8.7% Y/Y) and the consensus Revenue Estimate is $0.7M Over the last 3 months, EPS estimates have seen 2 up...

Provention Bio to Report Second Quarter 2022 Financial Results on August 4, 2022 PR Newswire RED BANK, N.J. , July 28, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-me...

Companies with multibagger potential can be hard to find in the stock market, and some might be tempted to turn to Wall Street analysts for ideas and inspiration. That's not necessarily a bad move. But investors should always do their due diligence before pressing the buy button, regardless...

H.C. Wainwright reduced its price target on Provention Bio ( NASDAQ: PRVB ) to $18 from $25 to reflect impact of dilution on account of the recently announced equity financing . The brokerage maintained its Buy rating on PRVB ahead of possible FDA approval of t...

Provention Bio ( NASDAQ: PRVB ) has entered into a securities purchase agreement with institutional investors for the private placement of ~$60M of shares of its common stock and warrants to acquire 13,318,535 additional shares of its common stock. The private placement in...

Provention Bio Announces $60 Million Private Placement PR Newswire RED BANK, N.J. , July 7, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated dise...

Provention Bio ( NASDAQ: PRVB ) on Thursday said the U.S. FDA had extended its review period for the company's biologics license application for its lead drug candidate teplizumab by three months. The FDA is now set to decide on the application on or before Nov. 17. ...

Provention Bio Announces Extension of FDA User Fee Goal Date for Teplizumab to November 17, 2022 PR Newswire RED BANK, N.J. , June 30, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to inter...

Gainers: O2Micro International Limited (OIIM) +20%. Fluence Energy (FLNC) +7%. Allarity Therapeutics (ALLR) +7%. SIGA Technologies (SIGA) +6%. Blackbaud (BLKB) +5%. Losers: Redbox Entertainment  (RDBX) -10%. Pacific Biosciences of California (PACB) -6%. Jamf Holding  (JAMF...